Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)

INCLUSION CRITERIA * Males or females of any ethnic group * β-SG deoxyribonucleic acid (DNA) gene mutations at both alleles * Weakness demonstrated based on history of difficulty in running, jumping and climbing stairs * A 100 meter walk/run (MWR) test result: ≥40 % of predicted for age-, height-, gender-, and weight-matched healthy controls at the screening visit EXCLUSION CRITERIA * Active viral infection based on clinical observations * Cardiac magnetic resonance imaging (MRI) determined left ventricular ejection fraction (LVEF) \<40% * Serological evidence of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection * Diagnosis of (or ongoing treatment for) an autoimmune disease * Abnormal laboratory values considered clinically significant * Concomitant illness or requirement for chronic drug treatment that, in the opinion of the Principal Investigator, creates unnecessary risks for gene transfer. Other inclusion/exclusion criteria apply.